226 results about "Virus inhibitors" patented technology

The utility model discloses a sampling test tube for virus inhibitor detection and analysis, which relates to the technical field of sampling test tubes and comprises a test tube outer tube, a test tube inner tube is arranged on the inner surface of the test tube outer tube, and a sealing assembly is in threaded connection with the upper portion of the outer surface of the test tube outer tube. A connecting ring and a discharging assembly are fixedly mounted on the lower surface of the test tube outer tube, the connecting ring is located on the outer side of the discharging assembly, and the discharging assembly comprises a discharging tube. According to the test tube, the anti-slip strips are arranged, so that the test tube can be attached to fingers conveniently, the second sealing cover can be held conveniently and rotated conveniently, the second sealing cover is separated from the discharge pipe under the action of threads of the second sealing cover and the discharge pipe, the discharge pipe is opened, and a sample flows out of the discharge pipe from the bottom of the outer tube of the test tube, so that discharge of the sample is facilitated; samples and fragments can be separated through a filter screen, a discharge pipe is sealed through a piston, and the sealing performance of the piston and a second sealing cover is further improved by arranging a second sealing ring.

The invention relates to the technical field of biological medicines, in particular to an umbilical cord source mesenchymal stem cell exosome preparation, a preparation method and application in preparation of osteoarthritis medicines. The preparation is prepared by the method. The method comprises the following steps: pretreating umbilical cord-derived mesenchymal stem cells by adopting a pretreating agent; removing the pretreatment agent, and carrying out gradient centrifugation treatment on the pretreated umbilical cord source mesenchymal stem cells to obtain exosome precipitate; and re-suspending the exosome precipitate in a buffer solution containing a protease inhibitor to obtain the umbilical cord source mesenchymal stem cell exosome preparation. The application refers to the application of the preparation in preparation of osteoarthritis drugs. The problems of low yield and functional heterogeneity of EXO obtained by a conventional culture method are solved.

The invention discloses application of domoic acid in preparation of a largemouth bass frog virus inhibitor. The domoic acid disclosed by the invention is relatively low in cytotoxicity, and has an obvious inhibition effect on micropterus salmoides frog virus compared with other microalgal toxins. Further exploration shows that after the micropterus salmoides frog virus is in direct contact with the domoic acid for 12 hours, the micropterus salmoides frog virus is irregular in shape and is completely bright white, so that the domoic acid has a direct destructive effect on the micropterus salmoides frog virus. And the domoic acid can inhibit the process of releasing the micropterus salmoides frog virus to the outside of the cells.

The present disclosure relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

The invention relates to the technical field of plant tissue extraction, in particular to an efficient extraction method and application of ginseng callus-derived exosomes, the extraction method comprises the following steps: S1, mixing ginseng callus with a PBS buffer solution, homogenizing and filtering to obtain a filtrate; s2, adding a protease inhibitor and a deep eutectic solvent into the filtrate, uniformly mixing, and standing to obtain a mixed solution; s3, centrifuging and filtering the mixed solution, and reserving supernate; s4, carrying out ultracentrifugation on the supernatant, collecting the precipitate, and resuspending with PBS to obtain a resuspension; and S5, further filtering the resuspension to obtain a filtrate, and storing at low temperature. The ginseng callus exosome extracted by the extraction method disclosed by the invention can be applied to preparation of drugs or cosmetics with anti-oxidation, anti-inflammatory and anti-aging effects, and the technical problems of low extraction efficiency, insufficient purity, complex extraction operation and poor stability of the extracted exosome in the existing exosome extraction technology can be effectively solved.

The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

The invention discloses a combined reagent for detecting fungus (1-3)-beta-D glucan, a kit and a detection method of fungus (1-3)-beta-D glucan, and belongs to the technical field of biomedical detection. The serum sample treatment liquid comprises a carbonate buffer solution with the pH value of 9.5-10.5, bacillus licheniformis protease, CHAPS, a surfactant and a preservative. The protein denaturing agent stop buffer comprises a phosphate buffer, a protease inhibitor, BSA and other components. Under the mild weak alkaline condition, the combined action of protease and a denaturant is utilized, a fungus (1-3)-beta-D glucan antigen-antibody compound in serum is efficiently dissociated, an antibody is irreversibly inactivated, and meanwhile the antigen activity is kept. The method has the advantages of simple operation, no need of heating, centrifugation or strong corrosive reagents, high safety, no precipitation and no gel of the treated sample, and suitableness for subsequent immunological detection. The invention further provides a detection kit containing the solution and a corresponding detection method, and the detection accuracy and efficiency are remarkably improved.

Provided in the present application are a cyclic peptide mutant and use and product thereof for the preparation of a coronavirus inhibitor, belonging to the technical field of cyclic peptide drugs. The present application is optimized on the basis of the cyclic peptide 6L3-3P11R. The obtained cyclic peptide mutant can resist the enzyme digestion effect of pancreatic enzymes and exhibits further improved antiviral activity, which is of great significance for expanding antiviral applications of cyclic peptide drugs.

The invention belongs to the technical field of biology, and relates to an exosome preserving fluid and an exosome preserving method. The preservation solution comprises glycerol with the concentration of 4-6% (V / V), trehalose with the concentration of 0.5-1.5% (W / V), albumin with the concentration of 0.05-0.2% (W / V), a sterile protective agent with the concentration of 0.01-0.03% (W / V), vitamin E with the concentration of 0.05-0.1% (W / V), ethylenediamine tetraacetic acid with the concentration of 0.05-0.2 mM, a protease inhibitor with the concentration of 0.05-0.1 mM and a basic solvent of 0.1 M phosphate buffer solution. The invention relates to an exosome preserving fluid and an exosome preserving method which are extremely low in toxic effect on a human body and can effectively preserve exosomes and maintain biological activity of the exosomes.

The invention relates to a related substance of a coronavirus 3CLpro protease inhibitor compound as shown in a formula (IV), a preparation method of the related substance and application of the related substance as an impurity reference substance in detection of the related substance of the compound as shown in the formula (IV), and the scientificity and accuracy of impurity detection of the compound as shown in the formula (IV) can be effectively improved by taking the related substance as the reference substance. The impurity content of the compound of the formula (IV) and the preparation thereof can be effectively and conveniently monitored, and the quality of the compound of the formula (IV) and the preparation thereof is favorably controlled, so that the safety and effectiveness of the compound and the preparation thereof are ensured.

The present application discloses a myocardial N69 protein protective solution and a myocardial N69 protein detection kit. The present application designs a myocardial N69 protein protective solution, the ratio of which includes: 0.12% to 0.48% by mass of Tris-HCl buffer, 1% to 5% by mass of BSA or 0.1% to 0.5% by mass of caseinate sodium, 0.2% to 2% by mass of disodium EDTA, 5% to 20% by mass of trehalose, 0.02% to 0.06% by volume of a surfactant, and 0.08% to 0.12% by volume of a preservative, ProClin300; it also includes a protease inhibitor and a reducing agent. The present application also designs a myocardial N69 protein detection kit. The present application can effectively and long-term preserve N69 protein calibrants and can quickly and accurately detect N69 protein.

The application provides a whole-process cold-chain preservation method for fresh large yellow croaker, which is targeted to enzyme inhibition and gradient microenvironment regulation. The method provided by the application comprises the following steps: 1, soaking the freshly caught large yellow croaker in seawater containing endogenous protease inhibitor peptides of the large yellow croaker within 30 minutes after catching, and reducing the core temperature of the fish body to 3-4 DEG C; after the soaking is completed, the surface moisture of the fish body is blown dry with sterile wind; 2, packaging the large yellow croaker after the surface moisture of the fish body is blown dry, and storing the packaged large yellow croaker in an environment with a temperature of-0.5-1 DEG C and a relative humidity of 65%-75%, so as to realize the preservation of the fresh large yellow croaker. The method provided by the application can greatly improve the preservation effect, and the endogenous protease inhibitor peptides of the large yellow croaker do not destroy the nutritional components of the fish meat, do not change the original flavor, have no chemical preservative residues, meet the green food standard, and are safer than the existing chemical preservation and soaking preservation technologies.

The invention relates to process development of a preparation prescription of a coronavirus 3CL protease inhibitor compound Iscartrevir and a preparation method of the coronavirus 3CL protease inhibitor compound Iscartrevir. By strictly screening and optimizing the formula, the preparation with a specific prescription ratio is obtained. According to the preparation, the medicine stability is improved, through the overall synergistic effect of the dry granulation step, in the preparation process of the medicine components, the flowing property of totally mixed materials is good, and the sticking problem is further solved. Meanwhile, the preparation is simple in production process, short in production period, energy-saving, efficient, low in cost and suitable for industrial mass production.

The invention relates to the field of medicinal chemistry, in particular to a tetrahydroisoquinoline papain-like protease inhibitor shown in a formula (I) and application thereof.

Provided herein are methods for treating or preventing a disease caused by an veterinary coronavirus in a non-human animal suffering from a coronavirus infection, in particular a feline coronavirus infection.

The invention belongs to the field of medicinal chemistry, and relates to carbonyl fused heterocyclic derivatives used as ubiquitin-specific protease inhibitors, in particular to a compound shown in the formula (I), an isomer thereof or pharmaceutically acceptable salt thereof.

The present invention provides the use of 4,3',5'-trihydroxy resveratrol compounds in the preparation of coronavirus 3CL protease inhibitors. The present invention discovers that 4,3',5'-trihydroxy resveratrol and its analogs have the activity of inhibiting coronavirus 3CL protease, and can play an anti-coronavirus role by inhibiting the activity of coronavirus 3CL protease. Among them, piceatannol, oxyresveratrol, physcion, 2,6,3',5'-tetrahydroxy stilbene, cis-tartriloside, 4-hydroxy resveratrol, and 4,3',5'-trihydroxy resveratrol have a half-maximal inhibitory concentration (IC50) against SARS-CoV and SARS-CoV-2 3CL proteases lower than 10 μM, showing good anti-coronavirus 3CL protease effect, effectively inhibiting the activity of coronaviruses, and can potentially be used for the prevention and / or treatment of coronavirus infections, and further for the preparation of drugs for the prevention and / or treatment of coronavirus infections.

The present invention provides methods for the prevention or treatment of Erectile dysfunction (ED) by administering SLPIs to animals, such as male humans. These methods can be administer together with vitamin D and / or phosphodiesterase 5 inhibitors.

Aspects of the present disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBD"), such as ulcerative colitis ("UC") and / or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an outer surface of the core. In some cases, the protease inhibitor is a gligliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and / or small intestine of a subject administered the pharmaceutical dosage form. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., bacterial protease) to the large intestine (e.g., colon) and / or the small intestine of a subject.

The present invention provides a 3C-like protease inhibitor represented by formula (I), or a pharmaceutically acceptable salt or ester thereof, stereoisomers or tautomers, racemates, N-oxides, polymorphs, hydrates, solvates, isotope-labeled forms, prodrugs, or metabolites. The present invention also provides methods for preparing the compound, pharmaceutical compositions containing the compound, and the effects of the compound in treating or preventing diseases caused by viral infections. #imgabs0#

This application relates to a compound represented by Formula I, and its pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, hydrates, polymorphs, prodrugs, or isotope-labeled compounds. These compounds can be used as bunyavirus inhibitors to prepare medicaments for preventing and / or treating bunyavirus infection or a disease caused by a bunyavirus infection in a subject, or for inhibiting the replication or reproduction of a bunyavirus in a subject. #imgabs0#.

The present application relates to the technical field of biological medicine, in particular to a kind of umbilical cord-derived mesenchymal stem cell exosome preparation, preparation method and application in preparation of osteoarthritis drugs.The preparation is prepared by the method.The method comprises pretreating umbilical cord-derived mesenchymal stem cells with a pretreatment agent;discard the pretreatment agent, and gradient centrifugation treatment is carried out to the pretreated umbilical cord-derived mesenchymal stem cells, to obtain exosome precipitate;the exosome precipitate is resuspended in a buffer containing protease inhibitor to obtain umbilical cord-derived mesenchymal stem cell exosome preparation.The application is the application of the preparation in the preparation of osteoarthritis drugs.The present application solves the problems of low yield and functional heterogeneity of EXO obtained by conventional culture method.

A compound represented by formula I and a racemate, a stereoisomer, a tautomer, an isotopic marker, nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, a pharmaceutical composition comprising same, a preparation method therefor, and a pharmaceutical use thereof are described. The compound has the activity of inhibiting USP28 and / or USP25. The structure of the formula I is as follows.

The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

The application discloses an amino benzene sulfonamide derivative and application thereof. The structural general formula of the amino benzene sulfonamide derivative is shown in the following formula. The amino benzene sulfonamide derivative has good pepsin inhibitory activity, can effectively block the adhesion and reactivation of pepsin in the pharyngeal mucosa, and has super high selectivity in the internal proteinase family compared with other non-specific protease inhibitors, thereby significantly reducing the off-target risk of normal physiological proteases in the human body. In addition, the compound is particularly suitable for local spray administration in the throat, can maintain a high concentration in the lesion site, and overcomes the defect of traditional oral antacid drugs in the insufficient effect on non-acid reflux, thereby providing a new solution for the treatment of throat reflux diseases.

Herein is reported a nucleic acid comprising in operably linked form a nucleic acid encoding a selection marker, a nucleic acid encoding a self-cleaving peptide sequence, and a nucleic acid encoding a proteinaceous protease inhibitor. Further reported are methods for the recombinant production of a heterologous polypeptide using said nucleic acid as well as a cell comprising said nucleic acid according to the invention. Likewise reported is the use of the nucleic acid according to the invention for increasing the amount of the recombinantly produced heterologous polypeptide by reducing protease cleavage.

A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and / or human cathepsin L inhibitor, and / or may be used in the preparation of a medicament for treating and / or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and / or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.